Sedentary time, insomnia, and weight linked to high-risk thyroid nodules in retrospective cohort
Does sitting too much or poor sleep raise your risk for dangerous thyroid nodules?
A retrospective cohort study of 164 patients with thyroid nodules found that sedentary time >2 hours/day, insomnia, and elevated weight were…
Sitting too much, poor sleep, and higher weight raise the risk for dangerous thyroid nodules, while eating a diverse diet and smaller nodule…
Epigenomic ctDNA profiling identifies PDAC subtypes and improves prognostication over tissue-based methods in metastatic disease
Can a blood test predict pancreatic cancer subtypes better than tissue samples?
This multi-institutional cohort study evaluated epigenomic profiling of circulating tumor DNA (ctDNA) for subtyping pancreatic ductal adenoc…
A new blood test matches tissue samples and predicts patient outcomes better for metastatic pancreatic cancer, offering a hopeful step towar…
Feasibility of combining ESPEN guidelines and Ayurvedic concepts to personalize diets for cancer patients
A small feasibility study found combining Ayurveda and standard guidelines is possible for cancer patients
This feasibility study evaluated personalized meal plans in 33 consenting adult cancer patients over 4 weeks to 6 months.
Personalized meals blending Ayurveda and standard cancer guidelines improved diet quantity for 33 adult cancer patients with no safety conce…
Higher county-level socio-behavioral risk associated with increased breast and prostate cancer mortality in U.S. counties
County social factors linked to higher breast and prostate cancer death rates within racial groups
This cross-sectional review analyzed 3,141 U.S.
County-level social factors like education and housing link to higher breast and prostate cancer death rates within all racial groups studie…
FDA Approves Keytruda (pembrolizumab) for Treatment of Unresectable or Metastatic Melanoma
FDA approves new drug Keytruda for advanced skin cancer
The FDA has approved Keytruda, a PD-1-blocking antibody, for the treatment of patients with unresectable or metastatic melanoma.
FDA approves Keytruda to treat advanced skin cancer that cannot be removed by surgery or has spread to other parts of the body.
Systematic review examines HIF-1α role in digestive system inflammation and cancer
Could a single protein be fueling both gut inflammation and cancer?
A systematic review synthesizing existing literature found HIF-1α contributes to pathogenesis of inflammatory digestive diseases and promote…
A single protein called HIF-1α may be driving both gut inflammation and digestive cancers while helping tumors resist drugs and evade the im…
Case report: Orelabrutinib-rituximab with intravitreal methotrexate shows response in primary vitreoretinal lymphoma
Can a new drug combination help treat a rare eye cancer?
A case report with literature review describes one patient with primary vitreoretinal lymphoma (PVRL) treated with orelabrutinib and rituxim…
A new drug combination improved vision and controlled tumors in a patient with a rare eye cancer, with no reported side effects.
Case report describes complete remission in PDTC with combined radiotherapy and chemotherapy
Case report describes complete remission in advanced thyroid cancer patient after combined treatment
A case report and literature review examined a 55-year-old male with advanced poorly differentiated thyroid carcinoma (PDTC).
A 55-year-old man with advanced thyroid cancer achieved complete remission after combining local radiotherapy and intravenous chemotherapy.
Benmelstobart plus anlotinib improves progression-free survival versus pembrolizumab plus placebo in first-line PD-L1-positive advanced NSCLC
New drug combo may extend time before cancer grows in lung patients
This randomised, controlled, phase 3 trial evaluated benmelstobart plus anlotinib versus pembrolizumab plus placebo in patients with PD-L1-p…
A new drug combo may extend the time before cancer grows in lung patients who have not yet received treatment for their advanced disease.
Lu-PSMA-617 reduces disease progression versus deferred ADT in oligometastatic HSPC in phase 2 trial
Can a targeted radiation drug delay prostate cancer progression without hormone therapy?
A phase 2 randomized controlled trial of 58 men with biochemically recurrent oligometastatic hormone-sensitive prostate cancer found Lu-PSMA…
A targeted radiation drug delayed prostate cancer progression by 20 months in early-stage patients without requiring hormone therapy first.
PARPi combinations show no significant clinical improvement in adult patients with glioblastoma
PARPi drugs show limited benefit for glioblastoma due to brain barriers
This systematic review evaluated poly-ADP-ribose polymerase inhibitors (PARPi) combined with standard therapy for adult patients with gliobl…
A systematic review examined PARP inhibitors used with standard treatments for adult glioblastoma patients.
DIBH reduces radiation dose to heart and lungs in left-sided breast cancer VMAT
Breath-hold technique reduces radiation dose to heart during breast cancer treatment
A meta-analysis of 11 studies in left-sided breast cancer patients treated with VMAT found deep inspiration breath hold (DIBH) reduced mean …
Holding a deep breath during radiation therapy consistently lowers the dose to the heart, lungs, and other organs for left-sided breast canc…